Capricor Therapeutics, Inc.
$34.21
▲
6.61%
2026-04-21 05:53:00
www.capricor.com
NMS: CAPR
Explore Capricor Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.04 B
Current Price
$34.21
52W High / Low
$40.37 / $4.3
Stock P/E
—
Book Value
$5.33
Dividend Yield
—
ROCE
-33.78%
ROE
-46.56%
Face Value
—
EPS
$-2.26
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
231
Beta
0.48
Debt / Equity
4.75
Current Ratio
9.01
Quick Ratio
9.01
Forward P/E
-82.11
Price / Sales
—
Enterprise Value
$1.49 B
EV / EBITDA
-14.03
EV / Revenue
—
Rating
None
Target Price
$53.9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 2. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
| 3. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 4. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
| 5. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 6. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 7. | 4D Molecular Therapeutics, Inc. | $10.07 | — | $535.53 M | — | -30.52% | -27.57% | $12.34 / $2.88 | $8.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 11.13 M | — |
| Operating Profit | -29.16 M | -26.28 M | -27.72 M | -24.98 M | -7.7 M | — |
| Net Profit | -30.17 M | -24.57 M | -25.91 M | -24.39 M | -7.12 M | — |
| EPS in Rs | -0.52 | -0.43 | -0.45 | -0.42 | -0.12 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 22.27 M | 25.18 M | 2.55 M |
| Operating Profit | -108.14 M | -42.56 M | -24.08 M | -29.7 M |
| Net Profit | -105.04 M | -40.47 M | -22.29 M | -29.02 M |
| EPS in Rs | -1.83 | -0.7 | -0.39 | -0.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 355.95 M | 170.48 M | 58.73 M | 50.09 M |
| Total Liabilities | 50.16 M | 25.02 M | 36.13 M | 38.31 M |
| Equity | 305.79 M | 145.46 M | 22.6 M | 11.79 M |
| Current Assets | 322.94 M | 163.39 M | 50.86 M | 42.89 M |
| Current Liabilities | 35.84 M | 21.03 M | 31.27 M | 23.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -69.81 M | -40 M | -25.6 M | 4.92 M |
| Investing CF | 97.48 M | -116.18 M | 5.11 M | -35.07 M |
| Financing CF | 248.89 M | 152.77 M | 25.58 M | 4.87 M |
| Free CF | -81.54 M | -41.53 M | -27.64 M | 1.56 M |
| Capex | -11.72 M | -1.54 M | -2.05 M | -3.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -11.55% | 886.81% | — | — |
| Earnings Growth % | -81.57% | 23.2% | — | — |
| Profit Margin % | -181.71% | -88.52% | -1137.37% | — |
| Operating Margin % | -191.12% | -95.63% | -1163.93% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -175.3% | -91.39% | -1143.04% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.